Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1994-10-28
1997-04-08
Prior, Kimberly J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
514171, 514172, 514174, 514175, 514176, 540108, 540110, 552540, 552546, 552548, 552552, 552553, 552554, 552556, 552558, 552610, 552611, A61K 3156, C07J 7500, C07J 900
Patent
active
056188064
DESCRIPTION:
BRIEF SUMMARY
This application is a 371 of application PCT/US93/03778 filed Apr. 22, 1993.
FIELD OF THE INVENTION
The present invention relates to certain novel 17.alpha. and 17.beta. substituted acyl 3-carboxy aromatic A ting steroidal compounds, pharmaceutical compositions containing these compounds, and methods for using these compounds to inhibit steroid 5-.alpha.-reductase. Also invented are novel intermediates and processes useful in preparing these compounds.
DESCRIPTION OF RELATED ART
The class of steroidal hormones known as androgens is responsible for the physical characteristics that differentiate males from females. Of the several organs that produce androgens, the testes produce these hormones in the greatest amounts. Centers in the brain exert primary control over the level of androgen production. Numerous physical manifestations and disease states result when ineffective control results in excessive androgen hormone production. For example, acne vulgaris, seborrhea, female hirsutism, male pattern baldness and prostate diseases such as benign prostatic hypertropy are correlated with elevated androgen levels. Additionally, the reduction of androgen levels has been shown to have a therapeutic effect on prostate cancer.
Testosterone is the principal androgen secreted by the testes and is the primary androgenic steroid in the plasma of males. It now is known that 5-.alpha.-reduced androgens are the active hormones in some tissues such as the prostate and sebaceous gland. Circulating testosterone thus serves as a prohormone for dihydrotestosterone (DHT), its 5-.alpha.-reduced analogue, in these tissues but not in others such as muscle and testes. Steroid 5-.alpha.-reductase is a nicotinamide adenine dinucleotide phosphate (NADPH) dependent enzyme that converts testosterone to DHT. The importance of this enzyme in male development was dramatically underscored by the discovery of a genetic steroid 5-.alpha.-reductase deficiency in male pseudohermaphrodites. Imperato-McGinley, J., et al., (1979), J. Steroid Biochem. 11:637-648.
Recognition of the importance of elevated DHT levels in various disease states has stimulated many efforts to synthesize inhibitors of this enzyme. Among the most potent inhibitors identified to date are 3-carboxy-estra-1,3,5(10) triene steroidal derivatives.
A number of 5-.alpha.-reductase inhibiting compounds are known in the art. For example, et al., describes the interaction mechanism between rat prostatic steroid 5-alpha reductase and 3-carboxy- 17.beta.-substituted steroids; describes the new steroid class of A ring aryl carboxylic acids; describes the effect of inhibitors of steroid 5.alpha.-reductase in benign prostatic hyperplasia, male pattern baldness and ache; and Beckmann) describes steroidal 3-carboxylic acid derivatives as useful 5-.alpha.-reductase inhibitors.
However, none of the above references specifically suggests that any of the novel steroidal 17.alpha. or 17.beta.-substituted acyl 3-carboxy-estra 1,3,5(10) triene compounds of the present invention would have utility as potent testosterone 5-.alpha.-reductase inhibitors.
SUMMARY OF THE INVENTION
This invention relates to a compound of the formula I: ##STR3## wherein Z is .alpha. or .beta. ##STR4## in which A is absent or present as a linear or branched, saturated or unsaturated hydrocarbon chain containing from 1-12 carbon atoms; and R is substituted alkyl, cycloalkyl or aryl, where hydrocarbon chain containing from 1-12 carbon atoms substituted with one or more substituents selected from the group consisting off aryloxy, alkoxy, acyloxy, amino, N-acylamino, nitro, cyano, oxo, halogen, --C(O)OR.sup.6 and --S(O).sub.n R.sup.5, cycloalkyl, substituted C.sub.6 -C.sub.12 aryl, alkyl or alkyl substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, amino, N-acylamino, oxo, hydroxy, cycloalkyl, substituted cycloalkyl, aryloxy, --C(O)OR.sup.6, --S(O).sub.n R.sup.7, nitro, cyano, halogen, C.sub.6 -C.sub.12 aryl, substituted C.sub.6 -C.sub.12 aryl and protected --OH, where R.su
REFERENCES:
patent: 4954446 (1990-09-01), Holt et al.
patent: 5017568 (1991-05-01), Holt et al.
patent: 5212166 (1993-05-01), Panzerl et al.
Holt Dennis A.
Levy Mark A.
Dustman Wayne J.
Kinzig Charles M.
Lentz Edward T.
Prior Kimberly J.
SmithKline Beecham Corporation
LandOfFree
17.alpha. and 17.beta.-substituted estra-1,3,5(10)-triene-3-carb does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 17.alpha. and 17.beta.-substituted estra-1,3,5(10)-triene-3-carb, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 17.alpha. and 17.beta.-substituted estra-1,3,5(10)-triene-3-carb will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2397820